Database	Timespan	Search Strategy
Cochrane Hepato‐Biliary Group Controlled Trials Register	Date will be given at review stage.	(((((bil* or lithocholic* or chenodeoxycholic* or ursodeoxycholic* or deoxycholic* or dehydrocholic* or tauro‐deoxycholic* or obeticholic*) and acid*) or (LCA or CDCA or UDCA or DCA or DHCA or TDCA)) and derivat*) OR FXR agonist*) AND ((sclerosing and cholangitis) or PSC)
Cochrane Central Register of Controlled Trials (CENTRAL)	Latest issue.	#1 MeSH descriptor: [Bile Acids and Salts] explode all trees #2 ((((bil* or lithocholic* or chenodeoxycholic* or ursodeoxycholic* or deoxycholic* or dehydrocholic* or tauro‐deoxycholic* or obeticholic*) and acid*) or (LCA or CDCA or UDCA or DCA or DHCA or TDCA)) and derivat*) OR FXR agonist* #3 #1 or #2 #4 MeSH descriptor: [Cholangitis, Sclerosing] explode all trees #5 (sclerosing and cholangitis) or PSC #6 #4 or #5 #7 #3 and #6
MEDLINE (Ovid SP)	1946 to the date of search.	1. exp "Bile Acids and Salts"/ 2. (((((bil* or lithocholic* or chenodeoxycholic* or ursodeoxycholic* or deoxycholic* or dehydrocholic* or tauro‐deoxycholic* or obeticholic*) and acid*) or (LCA or CDCA or UDCA or DCA or DHCA or TDCA)) and derivat*) OR FXR agonist*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 3. 1 or 2 4. exp Cholangitis, Sclerosing/ 5. ((sclerosing and cholangitis) or PSC).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 6. 4 or 5 7. 3 and 6 8. (random* or blind* or placebo* or meta‐analys*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 9. 7 and 8
EMBASE (Ovid SP)	1974 to the date of search.	1. exp bile acid/ 2. (((((bil* or lithocholic* or chenodeoxycholic* or ursodeoxycholic* or deoxycholic* or dehydrocholic* or tauro‐deoxycholic* or obeticholic*) and acid*) or (LCA or CDCA or UDCA or DCA or DHCA or TDCA)) and derivat*) OR FXR agonist*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 3. 1 or 2 4. exp primary sclerosing cholangitis/ 5. ((sclerosing and cholangitis) or PSC).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 6. 4 or 5 7. 3 and 6 8. (random* or blind* or placebo* or meta‐analys*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 9. 7 and 8
Science Citation Index Expanded	1900 to the date of search.	#3 #2 AND #1 #2 TS=((sclerosing and cholangitis) or PSC) #1 TS=(((((bil* or lithocholic* or chenodeoxycholic* or ursodeoxycholic* or deoxycholic* or dehydrocholic* or tauro‐deoxycholic* or obeticholic*) and acid*) or (LCA or CDCA or UDCA or DCA or DHCA or TDCA)) and derivat*) OR FXR agonist*)